[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt reported routine equity compensation activity.

Rhea-AI Filing Summary

Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 21, 2026, 3,334 restricted stock units were converted into the same number of common shares at an exercise price of $0, increasing his directly held common stock to 43,548 shares. On January 22, 2026, he sold 1,421 common shares at a price of $93.3252 per share, leaving him with 42,127 common shares held directly. The filing notes that these shares were sold to cover tax withholding obligations tied to the vesting of the restricted stock units. Following the transactions, he also directly holds 6,666 restricted stock units, each representing the right to receive one share of common stock or its cash equivalent, with one-third of the award vesting annually from January 21, 2025 through the third anniversary.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 1,421 shs ($133K)

Approx. gross sale proceeds $133K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	1,421	$93.3252	$133K
Exercise	Restricted Stock Units	3,334	$0.00	$0.00
Exercise	Common Stock	3,334	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 6,666 contracts (Direct); Common Stock — 42,127 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
2. F2. Includes 269 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.
3. F3. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
4. F4. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		M		3,334	A	(1)	43,548(2)	D
Common Stock	01/22/2026		S(3)		1,421	D	$93.3252(1)	42,127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/21/2026		M			3,334	(4)	(4)	Common Stock	3,334	$0	6,666	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Includes 269 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.

3. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

4. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.